Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
announced that its shares will begin trading on the NYSE MKT today,
Friday, May 16, 2014. The company's ticker symbol will remain "PVCT" but
it will withdraw its shares from quotation on the OTCQB concurrent with
listing its shares on the NYSE MKT.
Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is
a huge milestone for Provectus Biopharmaceuticals, and I take a great
deal of personal satisfaction from this news. I believe that this will
enhance our shareholder value as well as broaden our shareholder base
and heighten our corporate profile in the capital markets."
NYSE MKT is a fully integrated trading venue within the NYSE Euronext
community and leverages the NYSE's advanced and innovative market model
to offer a premier venue for listing and trading the stocks of small
companies. The venue utilizes the trading, connectivity and routing
technologies of the NYSE platform and offers superior price discovery,
superior liquidity and reduced trading volatility. Listed companies
benefit from issuer-selected Designated Market Makers (DMM) that utilize
world-class NYSE trading systems to discover and improve prices, dampen
volatility, add liquidity and enhance value. In addition, NYSE
MKT-listed companies gain access to the brand visibility and are
eligible for the issuer services enjoyed by the NYSE Euronext community.
"We welcome Provectus to the NYSE community and look forward to a strong
partnership with the Company and its shareholders," said Scott Cutler,
Exective Vice President and Head of Global Listings at NYSE Euronext.
"Provectus will join other pharmaceutical companies that benefit from
NYSE's trusted and reliable platform to raise capital."
About IntercontinentalExchange Group, Inc.
IntercontinentalExchange Group, Inc. (NYSE:ICE) is the leading network
of regulated exchanges and clearing houses for financial and commodity
markets. ICE delivers transparent, reliable and accessible data,
technology and risk management services to markets around the world
through its portfolio of exchanges, including the New York Stock
Exchange, NYSE MKT, ICE Futures, Liffe and Euronext.
Trademarks of ICE and/or its affiliates include
IntercontinentalExchange, ICE, ICE block design, NYSE Euronext, NYSE,
New York Stock Exchange, LIFFE and Euronext. Information regarding
additional trademarks and intellectual property rights of
IntercontinentalExchange Group, Inc. and/or its affiliates is located at https://www.theice.com/terms.jhtml
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. Its novel oncology drug PV-10 is designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects. Its oncology focus is on melanoma, breast cancer and cancers of
the liver. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications. Its
dermatological drug PH-10 also targets abnormal or diseased cells, with
the current focus on psoriasis and atopic dermatitis. Provectus has
recently completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date thereof.
[ Back To NFVZone's Homepage ]